Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 28Unknown 11Terminated 9Recruiting 4Withdrawn 3Not yet recruiting 3Enrolling by invitation 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3Observational 2

Sponsor

Conditions

Breast Neoplasms 370Neoplasms 253Carcinoma, Non-Small-Cell Lung 224Prostatic Neoplasms 192Lung Neoplasms 142Colorectal Neoplasms 139Neoplasm Metastasis 132Pancreatic Neoplasms 131Leukemia, Myeloid, Acute 126Multiple Myeloma 123Lymphoma 115Carcinoma, Hepatocellular 111Ovarian Neoplasms 98Melanoma 97Recurrence 93Leukemia 89Head and Neck Neoplasms 89Leukemia, Lymphocytic, Chronic, B-Cell 86Brain Neoplasms 86Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Glioblastoma 77Lymphoma, Non-Hodgkin 73Squamous Cell Carcinoma of Head and Neck 71Lymphoma, Follicular 70Lymphoma, Large B-Cell, Diffuse 66Colonic Neoplasms 66Carcinoma, Renal Cell 62Hematologic Neoplasms 59Sarcoma 55Glioma 53

Interventions

Certolizumab Pegol 2Ustekinumab 1Adalimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Interventional × Crohn Disease × Clear all
NCT04655807 2025-04-27

DUET

Janssen Research & Development, LLC

Phase 2 Withdrawn

Crohn Disease

NCT00354367 2012-05-28

Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas

UCB Pharma

Phase 3 Withdrawn

Crohn Disease, Fistula

NCT00358683 2012-05-28

A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease

UCB Pharma

Phase 3 Withdrawn

Crohn Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡